0171U CPT® code: payer coverage and prior authorization

Payer policies and prior authorization for 0171U

Payer coverage policies that name 0171U

0171U appears in 16 coverage policies from Aetna, Blue Cross & Blue Shield of Mississippi, Blue Cross NC, BlueCross BlueShield of South Carolina, Regence, UnitedHealthcare.

PayerPolicyRole in policyReviewedDocument
AetnaTumor Markers (0352)not coveredAug 25, 2026payer document
Blue Cross & Blue Shield of MississippiGenetic Cancer Susceptibility Panels Using Next Generation Sequencingunproven / investigationalpayer document
Blue Cross & Blue Shield of MississippiNextgeneration Sequencing For The Assessment Of Measurable Residual Disease (A.2.04.147)unproven / investigationalpayer document
Blue Cross NCMinimal Residual Disease (MRD) AHS - M2175listed, no stanceJan 1, 2026payer document
BlueCross BlueShield of South CarolinaMinimal Residual Disease (CAM 251)listed, no stanceOct 1, 2025payer document
RegenceEvaluating the Utility of Genetic Panels (Genetic Testing 64)listed, no stanceJun 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (2026T0652H)listed, no stanceAug 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (CS372.F)listed, no stanceFeb 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Idaho Only) (CS372ID.D)listed, no stanceMay 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Kansas Only) (CS372KS.03)listed, no stanceFeb 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Kentucky Only) (CS372KY.06)listed, no stanceMar 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Nebraska Only) (CS372NE.E)listed, no stanceFeb 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for New Mexico Only) (CS372NM.F)listed, no stanceFeb 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Ohio Only) (CS372OH.G)listed, no stanceFeb 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Pennsylvania Only) (CS372PA.E)listed, no stanceFeb 1, 2026payer document
UnitedHealthcareMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for Tennessee Only) (CS372TN.F)listed, no stanceFeb 1, 2026payer document

Medicaid fee-for-service

Prior authorization required or conditional in IN, MS.

  • FL: $820.30 (lab_independent, non-facility), effective Jan 1, 2026
  • IL: $1063.34 (practitioner), effective Jan 1, 2022
  • KY: $1519.06 (lab), effective Jan 1, 2026
  • MS: $1367.15 (comprehensive), effective Jul 1, 2026
  • ND: $0.00 (physician), effective Aug 1, 2026
  • VT: $0.00 (outpatient_hospital_opps), effective Feb 1, 2026
  • WY: $0.00 (outpatient_hospital_apc, Children's Hospitals), effective Apr 1, 2026

From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.